Replies to post #236958 on Biotech Values

[vinmantoo]

ENTA investors appear pleased with ABBV’s $2.0B guidance for 2021 Mavyret sales (#msg-161451655). As has been discussed on this board ad nauseam, Mavyret will not have positive growth, but it should have a long tail.

I am quite pleased that the ENTA cash machine will continue and easily fund the development of NASH, HBV and RSV programs. Yes, and even Covid-19 anti-virals